logo
  

CureVac: CVnCoV Vaccine Candidate Protects Against South African Variant In Preclinical Study

CureVac N.V. (CVAC) published preclinical data showing that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 or the South African variant, and a strain of the original SARS-CoV-2 B1 lineage in a transgenic mouse model.

Igor Splawski, Chief Scientific Officer of CureVac, said: "To our knowledge, this is the first challenge study in a human ACE2 transgenic mouse model of severe disease that shows complete protection against one of the most threatening virus variants."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
When Can We Expect Starlink to Go Public? This question got an answer from Tesla and SpaceX CEO Elon Musk, who said he will only publicly list SpaceX's satellite internet service Starlink when its revenue is more predictable. Musk was responding to a users tweet, "Any thoughts on Starlink IPO we would love to invest in the future. Any thoughts on first dibs for Tesla retail investors?" John David McAfee, who founded the antivirus software company McAfee Associates, has been found dead in a prison cell in Spain shortly after a Spanish court agreed to extradite him to the US to face tax evasion charges, multiple reports said. He was arrested in Spain in October 2020 after being accused of failing to file tax returns for four years. While reporting financial results for the first quarter of fiscal 2022 on Thursday, drugstore chain Rite Aid Corp. (RAD) initiated its adjusted loss and total revenue guidance for the full-year 2022, below analysts' estimates. For fiscal 2022, the company now projects an adjusted loss in a range...
Follow RTT